Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-CTAG regimen for elderly AML
NCT05258799Phase 2Recruiting
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human thrombopoietin in acute myeloid leukemia (AML). Started Jan 2022; status: recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05258799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05258799.